About This Calculator

The Paclitaxel Dose Calculator is a clinical tool designed for healthcare professionals to determine appropriate chemotherapy doses for various treatment regimens. It computes patient-specific dosing based on key anthropometric and lab data, including height, weight, age, sex, and serum creatinine. The tool calculates Body Surface Area (BSA) using multiple standard formulas and estimates Creatinine Clearance (CrCl) via the Cockcroft-Gault equation to ensure precise dosing for both Paclitaxel and, when applicable, Carboplatin via the Calvert formula.

Outputs Explained

After processing the inputs, the calculator provides a clear summary of essential dosing information:

• Patient Parameters: Calculated Body Surface Area (BSA) in m², Body Mass Index (BMI), and estimated Creatinine Clearance (CrCl) in mL/min, including the weight basis used (e.g., actual, ideal, or adjusted).
• Paclitaxel Dose: The total calculated dose in milligrams (mg) based on the selected regimen's mg/m² value and the patient's BSA (with any specified cap applied). The corresponding volume in milliliters (mL) based on a standard 6 mg/mL concentration is also provided.
• Carboplatin Dose: For combination regimens, the total dose in milligrams (mg) is calculated using the Calvert formula, which incorporates the target Area Under the Curve (AUC) and the patient's renal function (CrCl). The volume in mL based on a 10 mg/mL concentration is included.
• Administration Details: Key information such as the standard infusion time, recommended diluent and final volume, and critical administration notes (e.g., use of non-DEHP tubing and an in-line filter).

How to Use the Calculator

Follow these steps to accurately calculate chemotherapy doses:

1. Enter Patient Data: Input the patient's height, weight, age, sex, and most recent serum creatinine level. Use the toggle buttons to select the correct units (e.g., cm/in, kg/lb, mg/dL/µmol/L).
2. Select Regimen: Choose the appropriate chemotherapy protocol from the regimen dropdown menu (e.g., Paclitaxel/Carboplatin for ovarian cancer, Weekly Paclitaxel for breast cancer).
3. Enter Regimen-Specifics: If a Carboplatin-containing regimen is selected, the "Target AUC" field will appear. Enter the desired AUC value (e.g., 5 or 6).
4. Configure Formulas & Caps (Optional): Select the desired BSA formula (Mosteller is the default). If required by institutional policy, enter a BSA cap (e.g., 2.2 m²) or a CrCl cap for the Calvert formula (e.g., 125 mL/min).
5. Calculate and Review: Click the "Calculate" button. The tool will display the final doses, volumes, and other key parameters. Always independently verify these results against institutional protocols and prescribing information before clinical use.

Dosing Overview

Paclitaxel dosing is primarily based on Body Surface Area (BSA). The standard dose and schedule vary significantly depending on the type of cancer, whether it is used as a single agent or in combination, and the treatment setting (e.g., adjuvant, neoadjuvant, or metastatic). For instance, a common dosing schedule for ovarian cancer in combination with Carboplatin is 175 mg/m² administered as a 3-hour intravenous infusion every 3 weeks. In contrast, a weekly dosing schedule of 80 mg/m² as a 1-hour infusion is often used for metastatic breast cancer. Dose adjustments are frequently required for toxicities, particularly neutropenia and peripheral neuropathy.

Regimen Modification or Sequencing

In oncology, "switching" typically refers to moving to a different line of therapy upon disease progression or unacceptable toxicity. This calculator assists in planning for specific, established sequences. For example, the "Dose-Dense AC -> T" regimen for breast cancer involves a sequence where patients first receive doxorubicin and cyclophosphamide (AC), followed by paclitaxel (T). The calculator is used to determine the correct paclitaxel dose when it is time to begin that part of the sequence. It does not provide guidance on when to switch therapies, which is a decision based on comprehensive clinical evaluation.

Management of a Missed Dose

Paclitaxel is administered in a controlled clinical setting by healthcare professionals, not by the patient at home. If a patient misses a scheduled infusion appointment, the oncology team should be contacted immediately. The clinical staff will determine the best course of action, which typically involves rescheduling the infusion as soon as possible. The decision to proceed, delay, or modify the treatment schedule depends on the patient's overall health, blood counts, and the specific treatment protocol.

Safety Alerts

The administration of Paclitaxel carries significant risks that require careful management. Key safety considerations include:

• Hypersensitivity Reactions (HSRs): Severe and sometimes fatal HSRs can occur. Premedication with corticosteroids (e.g., dexamethasone) and antihistamines (both H1 and H2 antagonists) is mandatory to reduce this risk.
• Myelosuppression: Bone marrow suppression, primarily neutropenia, is the principal dose-limiting toxicity. Blood counts must be monitored closely before each cycle.
• Peripheral Neuropathy: A common side effect that is cumulative and dose-dependent. Severe symptoms may necessitate dose reduction or discontinuation of therapy.
• Hepatic Impairment: Patients with liver dysfunction are at increased risk of toxicity. Dose adjustments are required based on bilirubin and transaminase levels.

Frequently Asked Questions

References

1. TAXOL® (paclitaxel) Injection Prescribing Information. Bristol-Myers Squibb Company. Revised: 10/2011.
2. Carboplatin Injection, USP Prescribing Information. Pfizer Inc. Revised: 01/2021.
3. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748-1756.
4. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
5. National Cancer Institute. Paclitaxel - NCI Drug Dictionary. Accessed 2023.